121 related articles for article (PubMed ID: 8450496)
41. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
Zackheim JA; Abercrombie ED
Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
[TBL] [Abstract][Full Text] [Related]
42. Attenuation of SCH 23390-induced alteration of striatal dopamine D1 receptor ontogeny by prolyl-leucyl-glycinamide in the rat.
Kostrzewa RM; Saleh MI
Neuropharmacology; 1989 Aug; 28(8):805-10. PubMed ID: 2571103
[TBL] [Abstract][Full Text] [Related]
43. [3H]A-69024: a non-benzazepine ligand for in vitro and in vivo studies of dopamine D1 receptors.
Kassiou M; Scheffel UA; Musachio JL; Stathis M; Dannals RF
Life Sci; 1995; 57(23):PL367-72. PubMed ID: 7475960
[TBL] [Abstract][Full Text] [Related]
44. The kinetics of [3H]SCH 23390 dissociation from rat striatal dopamine D1 receptors: effect of dopamine.
Farrell CB; O'Boyle KM
Eur J Pharmacol; 1994 Jun; 268(1):79-88. PubMed ID: 7925614
[TBL] [Abstract][Full Text] [Related]
45. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
46. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis.
West AR; Grace AA
J Neurosci; 2002 Jan; 22(1):294-304. PubMed ID: 11756513
[TBL] [Abstract][Full Text] [Related]
47. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
48. Stimulatory role of dopamine on fibroblast growth factor-2 expression in rat striatum.
Roceri M; Molteni R; Fumagalli F; Racagni G; Gennarelli M; Corsini G; Maggio R; Riva M
J Neurochem; 2001 Feb; 76(4):990-7. PubMed ID: 11181818
[TBL] [Abstract][Full Text] [Related]
49. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
Makman MH; Dvorkin B
Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
[TBL] [Abstract][Full Text] [Related]
50. Supersensitivity of striatal D2 dopamine receptors mediating inhibition of adenylate cyclase and stimulation of guanosine triphosphatase following chronic administration of haloperidol in mice.
Olianas MC; Onali P
Neurosci Lett; 1987 Aug; 78(3):349-54. PubMed ID: 2819791
[TBL] [Abstract][Full Text] [Related]
51. 5-HT2 receptor regulation of acetylcholine release induced by dopaminergic stimulation in rat striatal slices.
RamÃrez MJ; Cenarruzabeitia E; Lasheras B; Del Rio J
Brain Res; 1997 May; 757(1):17-23. PubMed ID: 9200494
[TBL] [Abstract][Full Text] [Related]
52. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat.
Graham WC; Crossman AR; Woodruff GN
Brain Res; 1990 Apr; 514(1):93-102. PubMed ID: 2113410
[TBL] [Abstract][Full Text] [Related]
53. Decreased striatal release of acetylcholine following withdrawal from long-term treatment with haloperidol: modulation by cholinergic, dopamine-D1 and -D2 mechanisms.
Friedman E; Wang HY; Butkerait P
Neuropharmacology; 1990 Jun; 29(6):537-44. PubMed ID: 2200974
[TBL] [Abstract][Full Text] [Related]
54. Quinolinic acid lesions of rat striatum abolish D1- and D2-dopamine receptor-mediated catalepsy.
Calderon SF; Sanberg PR; Norman AB
Brain Res; 1988 May; 450(1-2):403-7. PubMed ID: 2969764
[TBL] [Abstract][Full Text] [Related]
55. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
56. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
Hess EJ; Norman AB; Creese I
J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
[TBL] [Abstract][Full Text] [Related]
57. Interaction of flunarizine with dopamine D2 and D1 receptors.
Ambrosio C; Stefanini E
Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
[TBL] [Abstract][Full Text] [Related]
58. Investigation of rat striatal dopamine D-1 receptors solubilized by digitonin with a precipitation method.
Zhang X; Segawa T
Eur J Pharmacol; 1989 Aug; 166(3):401-10. PubMed ID: 2680521
[TBL] [Abstract][Full Text] [Related]
59. Alteration of D1 and D2 dopaminergic receptor kinetics in specific rat brain regions following repeated administration of opiates.
Elwan MA; Soliman MR
Pharmacology; 1995 Aug; 51(2):73-83. PubMed ID: 8584575
[TBL] [Abstract][Full Text] [Related]
60. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
Tarazi FI; Florijn WJ; Creese I
Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
